At Endo, our far-reaching vision is simple: to help everyone we serve live their best life. As a specialty pharmaceutical company, we’re motivated by a strong sense of purpose to find better ways to meet unique medical needs.
Our global team of passionate employees understands the importance of their work. We’re dedicated to supporting one another as we connect with communities and foster partnerships that elevate quality-of-life and bring the best treatments forward.
Our uncompromising commitment results in the delivery of life-enhancing therapies. From intelligent product selection to commercialization, we strive to make a meaningful, tangible impact to help everyone live their best life.
Endo has global headquarters in Dublin, Ireland and its U.S. corporate office in Malvern, Pennsylvania.
(alprostadil for injection)
(testosterone) Gel CIII
(frovatriptan succinate) Tablets
(Lidocaine Patch 5%)
(oxycodone hydrochloride and acetaminophen USP) Tablets CII
(testosterone gel) Clll
(theophylline anhydrous) Extended-release capsules
(valrubicin) Sterile Solution for Intravesical Instillation
(collagenase clostridium histolyticum) for injection, for intralesional use
Par Pharmaceutical: High-Quality Generic Products
Par Pharmaceutical develops, manufactures and markets innovative generic pharmaceutical and branded injectable products that help improve patient quality of life. Par, among the top leaders in the U.S. generics industry, possesses an expanding portfolio that includes sterile injectables, alternative dosage forms and other differentiated products.
Paladin Labs Inc. is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing and sales organization that has helped it evolve into a well-known Canadian specialty pharmaceutical company with a breadth of products.
Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting September 21, 2023 7:45am
DUBLIN , Sept. 21, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis will be presented during the American Orthopaedic Foot & Ankle Society's (AOFAS) annual
View this post
Paladin Labs Announced Favourable CADTH Recommendation for XCOPRI™ (cenobamate tablets) Français September 12, 2023 7:30am
MONTREAL, Sept. 12, 2023 /CNW/ -- Paladin Labs Inc. announced today that the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended that XCOPRI ™ (cenobamate tablets) be publicly reimbursed as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy
View this post
ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS August 8, 2023 7:45am
DUBLIN , Aug. 8, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today reported financial results for the second-quarter ended June 30, 2023 . SECOND-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended June 30 , Six Months Ended June 30 , 2023 2022
View this post
Endo Announces First Patient Enrolled in Registry of Peyronie's Disease July 20, 2023 7:30am
DUBLIN , July 20, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in CURVE-PD (Clinical Understanding through Real-world data to Validate Effectiveness of treatments in Peyronie's disease), a non-interventional registry of up to
View this post
Endo Launches Bivalirudin Injection in Ready-to-Use Vials July 18, 2023 4:30pm
Only ready-to-use liquid format of bivalirudin on the market Does not require reconstitution, dilution or mixing, which helps increase efficiency for hospitals and healthcare providers DUBLIN , July 18, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that its Par Sterile
View this post
Endo and Premier, Inc. Collaborate to Address Pitocin® (oxytocin injection, USP) Shortage July 17, 2023 4:30pm
Strategic effort aims to bring stable, quality supply to providers and enhanced pricing predictability for critical labor and delivery drug CHARLOTTE, N.C. and DUBLIN , July 17, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) and Premier, Inc.
View this post
